Latest Lead News

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

Investigator Resources is advancing its South Australian silver projects with planned drilling at the Athena Prospect and inaugural copper-gold drilling at Curnamona, backed by a recent $4.3 million capital raise and new leadership.

Argent Minerals has delineated multiple extensive geophysical targets at its Kempfield Deposit and confirmed bonanza-grade gold mineralisation at Trunkey Creek, extending the known strike length to 4.7km. The company remains well-funded as it advances exploration.

QPM Energy has launched its Isaac Energy Hub and completed a major overhaul of the Townsville Power Station, setting the stage for a final investment decision on its Isaac Power Station by year-end.

SportsHero Limited has raised $1.65 million through a private placement to boost its e-sports gaming and community platforms, targeting new partnerships and market growth in Southeast Asia.

Apollo Minerals reports promising Phase 2 drilling results at its Salanie Gold Project in Gabon, revealing significant gold mineralisation and advancing exploration at its zinc and copper assets.

Odyssey Gold Limited has advanced its Tuckanarra Gold Project with a new mill access agreement, ongoing drilling, and a $4 million capital raise, positioning the company for a potential resource upgrade.

Viridis Mining and Minerals has raised AU$11.5 million through a heavily oversubscribed placement, strengthening its balance sheet to advance the Colossus Rare Earth Project towards Final Investment Decision. The funding, backed by institutional and strategic Brazilian partners, positions Viridis with nearly AU$58.5 million in cash to accelerate development and regulatory approvals.

NGX Limited progresses its Malingunde graphite project with technical studies and stakeholder engagement, while uranium exploration permits advance in Namibia. The company stands to benefit from new US anti-dumping tariffs on Chinese graphite imports.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Micro-X has secured its first supply agreement with a leading US healthcare provider for its Rover Plus mobile radiology system, opening access to over 700 facilities nationwide.